tbuckley/cabot-search huggingface dataset:
Abstract 9545: Indexing Mitral Regurgitant Volume to Left Ventricular Cavity Size Improves Prognostication of Mortality
Authors: Jordan B Strom, Marwa Sabe, A. Reshad Garan, Jason D Matos, Kamal R Khabbaz, Lawrence Markson, Warren J Manning
Journal: Circulation (2021)

Background: Indexing mitral regurgitation (MR) regurgitation volume (RVol) for left ventricular (LV) cavity size accounts for concomitant LV remodeling, but whether it improves prognostication of mortality is uncertain. Methods: The ratio of RVol to LV end-diastolic diameter (LVDD) was measured in 399 individuals (mean age 70.1 ±16.4 years, 51.1% female) with any MR (mean RVol 49.2 ± 27.7 mL) undergoing echocardiography (TTE). Individuals with prior mitral valve interventions were excluded. The relationship between RVol/LVDD and all-cause mortality was examined. The incremental predictive value of RVol/LVDD was compared to RVol alone. Results: Over a median (interquartile range) of 8.8 (3.4-10.5) years follow-up, there were 101 deaths (25.3%). Amongst those treated medically (N = 348), a lower ratio was associated with higher mortality (HR per 1-mL/cm decrease, 1.04, 95% CI 1.01-1.10, p = 0.04), despite a lesser degree of MR (low vs. high RVol/LVDD group, mean RVol, 30.3 ± 11.7 mL vs. 68.1 ± 26.3 mL, p &lt; 0.001), with an inflection for increased risk &lt; 8.4 mL/cm ( Figure ). By contrast, amongst those treated surgically (N = 41), no association was observed (p = 0.69) between RVol/LVDD and mortality, though death was less frequent. This association with risk was observed only amongst individuals with a reduced LVEF and was independent of etiology of MR (e.g. secondary vs. primary). Compared to RVol alone, indexing for LV cavity size improved the prognostication of death (p &lt; 0.001). Conclusions: Amongst patients with MR with a reduced LVEF, treated medically, survival was significantly worse amongst individuals with lower RVol/LVDD ratios. Furthermore, indexing for LV cavity size improved prediction of mortality compared to RVol alone. These results overall suggest that RVol should be routinely indexed for LV size to improve prognostication of risk. Moreover, they suggest a threshold may exist where LV size predominates risk in individuals with MR, treated medically.
Evaluation of Platelet Function Defects in Patients with Immune Thrombocytopenia
Authors: Elena Monzón Manzano, María Teresa Alvarez Román, Andres Ramirez Lopez, Elena G Arias-Salgado, Paula Acuña, Mónica Martín, María Isabel Rivas Pollmar, Sara García Barcenilla, Tamara Cebanu, Miguel Canales, Víctor Jiménez-Yuste, Nora V. Butta
Journal: Blood (2021)
Abstract PO-093: JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1
Authors: Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub
Journal: Cancer Research (2021)

Abstract Introduction: Pancreatic cancer cells are exposed to multiple stressors with both endogenous (proliferation, metabolism and nutrient deprivation) and exogenous (medical treatment) origins. The c-Jun N-terminal protein kinases (JNKs) JNK1 and JNK2 are important stress-activated kinases, responsible for the cellular response to these stressors. Both were demonstrated to exert both tumor-suppressing and tumor-promoting effects in human cancers Most previous studies rely on nonspecific pharmacological JNK inhibition. In this study, we planned to determine the isoform-specific roles in PDAC. Methods: Specific JNK1- and JNK2-knockdown (KD) clones were established in cultured human pancreatic cancer cell lines MIA PaCa-2 and PANC-1 by using specific shRNA plasmids. Anchorage dependent and independent growth, as well as migration and invasion, were analyzed in JNK-1/2 KD clones and compared to pharmacological JNK inhibition using SP600125. Xenograft growth was assessed using an orthotopic mouse model. Mechanistically, we assessed changes in EMT markers both in vitro and in vivo. Results: JNKs were expressed in both cultured pancreatic cancer cell lines as well as in resected human pancreatic cancer samples. Specific downregulation of JNK2 resulted in an overall increase in cell proliferation, invasion and alterations in cytoskeleton structure, while JNK1-KD revealed opposite effects. Nonspecific JNK-inhibition using SP600125 inhibited cell growth of all cell lines except PANC-1. Conclusion: JNK1 and JNK2 play opposing roles in human pancreatic cancer. Specifically targeting JNK1 with the retained function of JNK2 may provide a potential, individualized approach for targeting pancreatic cancer progression. Citation Format: Jingwei Shi, Xiaodong Tian, Marko Kornmann, Benno Traub. JNK2 suppresses the growth and invasion of pancreatic cancer and is opposed by JNK1 [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-093.
Selective Inhibition of Class II HDAC Isoforms 4 and 5 Provides a Promising Therapeutic Intervention for <i>MLL</i>-Rearranged Acute Lymphoblastic Leukemia in Infants
Authors: Tamara C.A.I. Verbeek, Susan Arentsen-Peters, Patricia Garrido Castro, Sandra Pinhancos, Kirsten Vrenken, Aida Varela-Moreira, M. Emmy Dolman, Bianca Koopmans, Rob Pieters, Ronald W. Stam
Journal: Blood (2021)
Urine Proteomics and Renal <scp>Single‐Cell</scp> Transcriptomics Implicate Interleukin‐16 in Lupus Nephritis
Authors: Andrea Fava, Deepak A. Rao, Chandra Mohan, Ting Zhang, Avi Rosenberg, Paride Fenaroli, H. Michael Belmont, Peter Izmirly, Robert Clancy, Jose Monroy Trujillo, Derek Fine, Arnon Arazi, Celine C. Berthier, Anne Davidson, Judith A. James, Betty Diamond, Nir Hacohen, David Wofsy, Soumya Raychaudhuri, William Apruzzese, Jill Buyon, Michelle Petri
Journal: Arthritis & Rheumatology (2021)

Objective Current lupus nephritis (LN) treatments are effective in only 30% of patients, emphasizing the need for novel therapeutic strategies. We undertook this study to develop mechanistic hypotheses and explore novel biomarkers by analyzing the longitudinal urinary proteomic profiles in LN patients undergoing treatment. Methods We quantified 1,000 urinary proteins in 30 patients with LN at the time of the diagnostic renal biopsy and after 3, 6, and 12 months. The proteins and molecular pathways detected in the urine proteome were then analyzed with respect to baseline clinical features and longitudinal trajectories. The intrarenal expression of candidate biomarkers was evaluated using single‐cell transcriptomics of renal biopsy sections from LN patients. Results Our analysis revealed multiple biologic pathways, including chemotaxis, neutrophil activation, platelet degranulation, and extracellular matrix organization, which could be noninvasively quantified and monitored in the urine. We identified 237 urinary biomarkers associated with LN, as compared to controls without systemic lupus erythematosus. Interleukin‐16 (IL‐16), CD163, and transforming growth factor β mirrored intrarenal nephritis activity. Response to treatment was paralleled by a reduction in urinary IL‐16, a CD4 ligand with proinflammatory and chemotactic properties. Single‐cell RNA sequencing independently demonstrated that IL16 is the second most expressed cytokine by most infiltrating immune cells in LN kidneys. IL‐16–producing cells were found at key sites of kidney injury. Conclusion Urine proteomics may profoundly change the diagnosis and management of LN by noninvasively monitoring active intrarenal biologic pathways. These findings implicate IL‐16 in LN pathogenesis, designating it as a potentially treatable target and biomarker.
Increased Bone Marrow Iron at Diagnosis Is Associated with Inferior Prognosis in Patients with Myelodysplastic Syndromes
Authors: Annika Kasprzak, Sandra Becker, Martina Rudelius, Corinna Strupp, Kathrin Nachtkamp, Judith Strapatsas, Barbara Hildebrandt, Norbert Gattermann, Ulrich Germing
Journal: Blood (2021)
Upregulation of CD47 Expression in <i>De Novo</i> Diffuse Large B-Cell Lymphoma Is More Frequent in Activated B-Cell Type
Authors: Winston Y Lee, Anamarija M. Perry, Vero Azcutia, Alex F. Herrera, Pamela Skrabek, Ryan Jackson, Raju Pillai, Victoria Bedell, Jennifer Brazil, Joyce Murata-Collins, Wing C. Chan, Dennis D. Weisenburger, Charles Parkos, Joo Y. Song
Journal: Blood (2021)
Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
Authors: Jessica S. Little, Parth Shah, Adam S. Sperling, Andrew R. Branagan, Omar Nadeem, Andrew J. Yee, Noopur S. Raje, Nikhil C. Munshi, Sarah Hammond
Journal: Blood (2021)
Follicular Lymphoma Microenvironment Signatures Define Patients Subsets Obtaining Long Term Clinical Benefit after Single-Agent First-Line Anti-CD20 Immunotherapy
Authors: Enrico Derenzini, Marcello Del Corvo, Maria Chiara Quattrocchi, Marta Castelli, Maria Rosaria Sapienza, Saveria Mazzara, Stefano Fiori, Anna Vanazzi, Safaa M. Ramadan, Stefano A Pileri, Corrado Tarella
Journal: Blood (2021)
IND-Enabling Studies of a Switchable Chimeric Antigen Receptor-T Cell (CLBR001+SWI019) to Support First in Human Clinical Study
Authors: Eduardo Laborda, Ashley Woods, Andrew Doedens, Yunyi Kang, Vanessa Nunez, Sean Joseph, Michael Emde, Jennifer Stone, Jing Li, Mohit Trikha, Peter G. Schultz, Travis S Young
Journal: Blood (2021)
Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies
Authors: Jaewoong Lee, Mark E. Robinson, Ning Ma, Kohei Kume, Dewan Artadji, Teresa Sadras, Kadriye Nehir Cosgun, Huimin Geng, Elisabeth M. Paietta, Maike Buchner, Nagarajan Vaidehi, David M. Weinstock, Markus Müschen
Journal: Blood (2021)
Clinical and Molecular Characteristics Associated with Vitamin C Deficiency in Myeloid Malignancies; Real World Data from a Prospective Cohort
Authors: Naveen Premnath, Stephen Chung, Suleyman Y Goksu, Prapti Patel, Ruth Ikpefan, John Rolwes, Mohak Pandey, Gurbakhash Kaur, Praveen Ramakrishnan, Ankit Kansagra, Farrukh T. Awan, Larry D. Anderson, Madhuri Vusirikala, Robert H. Collins, Michalis Agathocleous, Yazan F. Madanat
Journal: Blood (2021)
Abstract #4035: Serotonin: A neurotransmitter as well as a potent angiokine
Authors: Anshu Roy, Ali Zamani, Subramaniam Ananthan, Zhican Qu
Journal: Cancer Research (2009)

Serotonin (5-HT), an endogenous biogenic amine, has been recognized as an important neurotransmitter involved in many functions in central nervous system. Initially, 5-HT was identified as a powerful peripheral blood vasoconstrictor. Recently, 5-HT is emerging as a key mediator in different biological processes, including angiogenesis. However, the mechanism of action of 5-HT in the angiogenic process has not been established yet. Angiogenesis is a multi-step process initiated by endothelial cell activation. Targeting angiogenesis has become an effective treatment for several human diseases, including cancer. We studied the effects of 5-HT on key endothelial processes in angiogenesis. The results have shown that 5-HT is able to activate human endothelia potently by stimulating their proliferation and migration, and promoting the cell differentiation into capillary tubes. Experiments with 5-HT receptor antagonists demonstrated that 5-HT mediated endothelia activation is probably via 5-HT receptor 1 and 2, which have been shown to be expressed in human artery and vein endothelial cells. Immunostaining experiments also demonstrated serotonin receptor expression located at blood microvessels within xenograft tumors, suggesting serotonin signaling may be involved in tumor angiogenesis. Our results suggest that 5-HT is a potent angiogenic factor and serotonin signaling could be a novel target for modulating angiogenesis.  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4035.
TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer
Authors: Mengyu Tu, Lukas Klein, Elisa Espinet, Theodoros Georgomanolis, Florian Wegwitz, Xiaojuan Li, Laura Urbach, Adi Danieli-Mackay, Stefan Küffer, Kamil Bojarczuk, Athanasia Mizi, Ufuk Günesdogan, Björn Chapuy, Zuguang Gu, Albrecht Neesse, Uday Kishore, Philipp Ströbel, Elisabeth Hessmann, Stephan A. Hahn, Andreas Trumpp, Argyris Papantonis, Volker Ellenrieder, Shiv K. Singh
Journal: Nature Cancer (2021)
YAP/TAZ Promote Hematopoietic Regeneration Via Accelerating the Recovery of Bone Marrow Niche
Authors: Shun Uemura, Masayuki Yamashita, Ayako Aihara, Takumi Iwawaki, Shuhei Koide, Yaeko Nakajima-Takagi, Motohiko Oshima, Masayoshi Masuko, Jun Takizawa, Hirohito Sone, Taito Nishino, Atsushi Iwama
Journal: Blood (2021)
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
Authors: Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fürstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Müller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
Journal: Blood (2021)
Analysis of Single Cell Transcriptomics in Paired Pediatric T-ALL Samples Collected at Diagnosis and Following End of Induction Therapy Reveals an MRD-Associated Stem Cell Signature
Authors: Swati S Bhasin, Beena E Thomas, Ryan J Summers, Debasree Sarkar, Hope L Mumme, Mohammed Emam Mansour, William Pilcher, Sunita I. Park, Sharon M. Castellino, Deborah DeRyckere, Manoj Bhasin, Douglas K Graham
Journal: Blood (2021)
Development of a Fast and Reproducible Assay for the Clinical Implementation of Epigenetic Biomarkers to Predict Decitabine Response in Patients with Chronic Myelomonocytic Leukemia
Authors: Masataka Taguchi, Maikel Anthonissen, Aristeidis G. Telonis, Qin Yang, Eric Solary, Valeria Santini, Maria E. Figueroa
Journal: Blood (2021)
An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis
Authors: Adi Zoref-Lorenz, Jun Murakami, Liron Hofstetter, Swaminathan Iyer, Ahmad S. Alotaibi, Shehab Fareed Mohamed, Peter G. Miller, Elad Guber, Shiri Weinstein, Joanne Yacobovich, Sarah Nikiforow, Benjamin L. Ebert, Adam Lane, Oren Pasvolsky, Pia Raanani, Arnon Nagler, Nancy Berliner, Naval Daver, Martin Ellis, Michael B. Jordan
Journal: Blood (2021)
Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma
Authors: Noopur S. Raje, Nina Shah, Sundar Jagannath, Jonathan L. Kaufman, David S. Siegel, Nikhil C. Munshi, Jacalyn Rosenblatt, Yi Lin, Andrzej Jakubowiak, Alison Timm, Ashish Yeri, Nathan Martin, Timothy B. Campbell, Olivia Finney, Anna Truppel-Hartmann, Fabio Petrocca, Jesús G. Berdeja, Melissa Alsina
Journal: Blood (2021)
Comparison of Tumor Lysis Syndrome (TLS) Risk Reduction and Incidence in Different Venetoclax-Based Combinations within the Randomized Phase 3 GAIA (CLL13) Trial
Authors: Moritz Fürstenau, Sandra Robrecht, Can Zhang, Julia Von Tresckow, Carsten Utoft Niemann, Arnon P. Kater, Michael Gregor, Patrick Thornton, Philipp B. Staber, Tamar Tadmor, Mark-David Levin, Caspar Da Cunha-Bang, Christof Schneider, Christian Bjørn Poulsen, Thomas Illmer, Björn Schöttker, Ann Janssens, Ilse Christiansen, Thomas Noesslinger, Michael Baumann, Florian Simon, Nisha De Silva, Anna-Maria Fink, Kirsten Fischer, Clemens-Martin Wendtner, Matthias Ritgen, Monika Brüggemann, Eugen Tausch, Marinus H.J. Van Oers, Christian H. Geisler, Stephan Stilgenbauer, Michael Hallek, Barbara Eichhorst
Journal: Blood (2021)
A Phase II Study Evaluating Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients with Previously Untreated Double and Triple Hit Lymphoma
Authors: Dipenkumar Modi, Seongho Kim, Silva Pregja, Christiane Houde, Kathy A. Reichel, Rod Ramchandren
Journal: Blood (2021)
Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry
Authors: Rami S. Komrokji, Tracy I. George, Harry P. Erba, Bart L. Scott, David L. Grinblatt, Jaroslaw P. Maciejewski, Gail J. Roboz, Michael R. Savona, Guillermo Garcia-Manero, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Mikkael A. Sekeres
Journal: Blood (2021)
Suicide in African American Adolescents: Understanding Risk by Studying Resilience
Authors: W. LaVome Robinson, Christopher R. Whipple, Kate Keenan, Caleb E. Flack, LaRicka Wingate
Journal: Annual Review of Clinical Psychology (2021)

Historically, suicide rates for African American adolescents have been low, relative to rates for youth of other racial-ethnic backgrounds. Since 2001, however, suicide rates among African American adolescents have escalated: Suicide is now the third leading cause of death for African American adolescents. This disturbing trend warrants focused research on suicide etiology and manifestation in African American adolescents, along with culturally sensitive and effective prevention efforts. First, we revisit leading suicide theories and their relevance for African American adolescents. Next, we discuss health promotive and protective factors within the context of African American youth development. We also critique the current status of suicide risk assessment and prevention for African American adolescents. Then, we present a heuristic model of suicide risk and resilience for African American adolescents that considers their development within a hegemonic society. Finally, we recommend future directions for African American adolescent suicidology.
Blinatumomab for Patients with Richter's Syndrome: A Multicenter Phase 2 Trial from the Filo Group
Authors: Romain Guieze, Loic Ysebaert, Damien Roos-Weil, Lysiane Molina, Luc Mathieu Fornecker, Thérèse Aurran, Anne-Sophie Michallet, Emmanuelle Ferrant, Aline Clavert, Alain Saad, Sophie de Guibert, Bernard Drenou, Philippe Quittet, Bénédicte Hivert, Kamel Laribi, Julie Gay, Julien Broséus, Valérie Rouille, David Schwartz, Bruno Pereira, Alain Delmer, Pierre Feugier
Journal: Blood (2021)
The Comparison of Dasatinib 70 Mg/Day to 100 Mg/Day in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Multicenter, Prospective, Randomized Controlled Study
Authors: Dan Yu, Zhuangzhi Yang, Hui Cheng, Rui Jiang, Jingming Guo, Chucheng Wan, Jun Qin, Youshan Zhang, Guolin Yuan, Daozi Jiang, Chun Zhang, Fang Liu, Min Zhang, Shiming Chen, Caixia Liang, Jing Zou, Zhiwei Wu, Xiuping Zou, Danlei Han, Xu Chen, Li Wang, Tingting Lv, Xiaolong Tian, Yanping Xie, Hongyu An, Li Yan, Yicheng Zhang, Weiming Li
Journal: Blood (2021)
Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study
Authors: Nathanael R Fillmore, Jennifer La, Julie Tsu-Yu Wu, Westyn Branch-Elliman, Linden Huhmann, Summer S Han, Giovanni Parmigiani, David P Tuck, Mary Brophy, Nhan V Do, Albert Y Lin, Nikhil C. Munshi
Journal: Blood (2021)
Learning disentangled representations in the imaging domain
Authors: Xiao Liu, Pedro Sanchez, Spyridon Thermos, Alison Q. O’Neil, Sotirios A. Tsaftaris
Journal: Medical Image Analysis (2022)

Disentangled representation learning has been proposed as an approach to learning general representations even in the absence of, or with limited, supervision. A good general representation can be fine-tuned for new target tasks using modest amounts of data, or used directly in unseen domains achieving remarkable performance in the corresponding task. This alleviation of the data and annotation requirements offers tantalising prospects for applications in computer vision and healthcare. In this tutorial paper, we motivate the need for disentangled representations, revisit key concepts, and describe practical building blocks and criteria for learning such representations. We survey applications in medical imaging emphasising choices made in exemplar key works, and then discuss links to computer vision applications. We conclude by presenting limitations, challenges, and opportunities.
Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
Authors: Jianning Ge, Chunhui Yang, Jing Sun, Jiao Chen, Shuyi Qiu, Wenjie Yin, Lianjun Shen, Martina Sersch, Wei Cao, Xinxin Wang
Journal: Blood (2021)
HSP90 inhibitor RGRN‐305 for oral treatment of plaque‐type psoriasis: efficacy, safety and biomarker results in an open‐label proof‐of‐concept study*
Authors: A. Bregnhøj, K.K.H. Thuesen, T. Emmanuel, T. Litman, C.L. Grek, G.S. Ghatnekar, C. Johansen, L. Iversen
Journal: British Journal of Dermatology (2021)

HSP90 is a downstream regulator of tumour necrosis factor (TNF)-α and interleukin (IL)-17A signalling and may therefore serve as a novel target in the treatment of psoriasis.This phase Ib proof-of-concept study was undertaken to evaluate the safety and efficacy of a novel HSP90 inhibitor (RGRN-305) in the treatment of plaque psoriasis.We conducted an open-label, single-arm, dose-selection, single-centre proof-of-concept study. Patients with plaque psoriasis were treated with 250 mg or 500 mg RGRN-305 daily for 12 weeks. Efficacy was evaluated clinically using the Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician's Global Assessment (PGA) scores and the Dermatology Life Quality Index (DLQI). Skin biopsies collected at baseline and at 4, 8 and 12 weeks after initiation of treatment were used for immunohistochemical staining and for gene expression analysis. Safety was monitored via laboratory tests, vital signs, electrocardiogram and physical examinations.Six of the 11 patients who completed the study responded to RGRN-305 with a PASI improvement between 71% and 94%, whereas five patients were considered nonresponders with a PASI response < 50%. No severe adverse events were reported. Four of seven patients treated with 500 mg RGRN-305 daily experienced a mild-to-moderate exanthematous drug-induced eruption owing to the study treatment. Two patients chose to discontinue the study because of this exanthematous eruption. RGRN-305 treatment resulted in pronounced inhibition of the IL-23, TNF-α and IL-17A signalling pathways and normalization of both histological changes and psoriatic lesion gene expression profiles in patients who responded to treatment.Treatment with RGRN-305 showed acceptable safety, especially in the low-dose group, and was associated with clinically meaningful improvement in a subset of patients with plaque psoriasis, indicating that HSP90 may serve as a novel future target in psoriasis treatment.